Gynecology, Obstetrics and Perinatology

Prevention of placental insufficiency in pregnant women at a high perinatal risk

The author presents the results of using dydrogesterone in 120 pregnant women at a high perinatal risk in a complex program of preventing placental insufficiency at terms 7–20 weeks of gestation. Along with control clinical, ultrasound, dopplerometric examinations, the levels of the vascular-endothelial growth factor and placental growth factor during pregnancy was studied in pregnant women who received dydrogesterone but did not receive it in the first half of pregnancy. It was shown that for prevention of placental insufficiency in pregnant women at a high perinatal risk the administration of dydrogesterone was pathogenetically  justified  at  the  stages  of  implantation  and  anatomic-functional  formation  of  the  placenta  determining  high  perinatal morbidity. Using dydrogesterone from 7 to 20 week, a decrease of occurrence of PI by 2.13 times was obtained. Perinatal morbidity in pregnant women of the reference group was 546‰, in the basic group – 272‰, i.e. perinatal morbidity decreased 2-fold. For  evaluation  of  the  efficacy  of  prevention  and  therapy  of  PI  not  only  laboratory  instrumental  examination  with  fetometry, dopplerometry but also dynamic determination of vascular-endothelial growth factor and placental growth factor is important.


Яндекс.Метрика